First patent issued in Europe for Orexo’s adrenaline product OX640
Uppsala, Sweden – September 1, 2022 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces that the European Patent Office (EPO) has granted the first European patent specifically relating to OX640, Orexo’s nasal adrenaline rescue medication based on the amorphOX® drug delivery platform. The new patent, EP 3 962 455 B1, provides protection for the OX640 product in Europe until May 2041. Orexo has multiple patent applications filed in other territories and expect to continuously strengthen the patent portfolio for OX640. Nikolaj Sørensen, President and CEO, said: “OX640